“An Audit to Evaluate the Clinical Safety and PSA Response of Firmagon® (Degarelix) in Patients with Advanced Metastatic Prostate Cancer -”, J. Can. Res. Updates, vol. 2, no. 1, pp.  21–25, Jan. 2013, doi: 10.6000/1929-2279.2013.02.01.4.